Annual report pursuant to Section 13 and 15(d)

Development Awards and Deferred Revenue (Details Narrative)

v3.19.1
Development Awards and Deferred Revenue (Details Narrative) - USD ($)
12 Months Ended
Jan. 26, 2018
Apr. 20, 2015
Dec. 31, 2018
Dec. 31, 2017
Nov. 30, 2017
Jan. 31, 2017
Aug. 31, 2016
Nov. 30, 2015
May 31, 2015
Development Award [Line Items]                  
Amount received upon achievement     $ 1,462,503          
Revenue     $ 4,822,272 2,440,195          
Warrant exercisable shares of common stock     5,000            
Additional paid in capital, fair value of warrant issued     $ 6,215,225            
Kaken Pharmaceutical Co., Ltd. [Member]                  
Development Award [Line Items]                  
Upfront payment, received from related party     27,000,000            
Cystic Fibrosis Foundation Warrants [Member]                  
Development Award [Line Items]                  
Revenue     18,784,775            
Warrant to purchase of common stock 1,000,000                
Warrant exercisable price per share $ 13.20                
Warrant exercisable shares of common stock 500,000                
Warrant expires date Jan. 26, 2025                
Additional paid in capital, fair value of warrant issued     6,215,225            
Maximum [Member]                  
Development Award [Line Items]                  
Amount received upon achievement     12,500,000            
2015 CFFT Award Agreement [Member]                  
Development Award [Line Items]                  
Amount received upon achievement         $ 500,000 $ 1,000,000 $ 1,000,000 $ 1,250,000 $ 1,250,000
Revenue     $ 2,440,195          
2015 CFFT Award Agreement [Member] | Oral Anti-inflammatory Drug [Member]                  
Development Award [Line Items]                  
Amount received upon achievement   $ 5,000,000              
2015 CFFT Award Agreement [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                  
Development Award [Line Items]                  
Payment due period after the first commercial sale   90 days              
Royalty payment, sales target   $ 500,000,000              
2015 CFFT Award Agreement [Member] | Maximum [Member]                  
Development Award [Line Items]                  
Development award received   5,000,000              
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Commercialization of the Product [Member]                  
Development Award [Line Items]                  
Royalty payable   25,000,000              
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]                  
Development Award [Line Items]                  
Royalty payable   5,000,000              
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Transfer Sale or Licensing [Member]                  
Development Award [Line Items]                  
Royalty payable   $ 15,000,000              
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                  
Development Award [Line Items]                  
Development award received $ 25,000,000                
Investment Agreement [Member]                  
Development Award [Line Items]                  
Revenue     4,822,272            
Reclassified to contract asset and classified in prepaid expenses     25,000,000            
Investment Agreement [Member] | Cystic Fibrosis Foundation [Member]                  
Development Award [Line Items]                  
Proceeds from Royalty     2,700,000            
Investment Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member] | 2018 CFF Award [Member]                  
Development Award [Line Items]                  
Proceeds from Royalty     2,700,000            
Upfront payment, received from related party     27,000,000            
Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                  
Development Award [Line Items]                  
Amount received upon achievement     $ 12,500,000            
Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]                  
Development Award [Line Items]                  
Warrant exercisable shares of common stock 500,000                
Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]                  
Development Award [Line Items]                  
Royalty payment percentage     10.00%